(Date:11/27/2009)...firm Replikins Ltd. today issued its latest bioche... shows that the lethality of the virus has dropped...s current outbreak in the spring of 2009 to restin... The H1N1 infectivity count, however, remains incr...ovember 27, 2009 -- Biotech firm Replikins Ltd., w...
(Date:11/27/2009)...7/PRNewswire-FirstCall/--ShamirOpticalIndustryLtd....vativeproductsandtechnologytotheophthalmiclensmark...dadividenddistributioninanaggregateamountofUS$10mi...er25,2009representativerateofexchange),orapproxima...25,2009representativerateofexchange)perordinarysha...
(Date:11/27/2009)...ealth™ announced today that Spectrum Health ...d Enterprise orthopedic templating solution and it... (PRWEB) November 27, 2009 -- Voyant...h (Grand Rapids, Michigan) has licensed its Trauma...its TraumaCad Extend workflow solution, to allow i...
(Date:11/26/2009)...wswire/--ThediabetespopulationintheUnitedStateswil...ndingonthediseaseisprojectedtohit$336billion,upfro...ecemberissueof DiabetesCare .TheNational ChangingD...commissionedtheanalysisbyateamfromtheUniversityofC...ericanslivingwithdiabeteswillrisefrom23.7millionin...
(Date:11/26/2009)...letters from the North Pole, Textsanta.net lets pa...Santa , North Pole, AK (P...ciencies at the North Pole Santa Claus has added S...he globe informed of his Christmas progress at the...epartment have identified a large and growing perc...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2(Date:11/25/2009)...25/PRNewswire/--RegadoBiosciences,aprivatelyheldco...withactivecontrolagents,announcedthatDavidMazzo,Ph...y21stAnnualHealthCareConferenceattheNewYorkPalaceH...nat1:10pm(EST)onTuesday,December1andwillincludeano...developmentprogram,theanticoagulantsystem,REG1.The...
(Date:11/25/2009)...5/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: ABAX ...ebloodanalysissystems,announcedtodaythatClintSever...the21stAnnualPiperJaffrayHealthCareConferenceonWed...lbeheldattheNewYorkPalaceHotelinNewYorkCity. ,,...dmarketsportablebloodanalysissystemsforuseinanyvet...
(Date:11/25/2009).../PRNewswire/--CempraPharmaceuticalsInc.todayannoun...tiveofficer,willpresentatthePiperJaffray21stAnnual...tTheNewYorkPalaceHotelinNewYorkCity.Dr.Fernandeswi...ticclinicalprogramsforthetreatmentofdrug-resistant...uticals ,, Foundedin2006,CempraPharmaceuticals...
Breaking Medicine Technology:Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 1AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 2AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 3AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 4Women 26apos 3Bs Health Expert Dr Susan Lark Featured on Searchbloodsugar com 50863 1Women 26apos 3Bs Health Expert Dr Susan Lark Featured on Searchbloodsugar com 50863 2Women 26apos 3Bs Health Expert Dr Susan Lark Featured on Searchbloodsugar com 50863 3Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 1Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 2Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 3Urgent 28R 29 PC and Macroplastique 28R 29 Featured in Numerous IUGA 2009 Sessions 50859 4... Dec. 9 Portola,Pharmaceuticals, a biopharmaceuti...de significant advances in cardiovascular disease,...that it has initiated patient enrollment in,INNOVA...28, the Company,s,novel P2Y12 ADP receptor antagon...s coronary intervention (PCI). , "With the i...
...nnium: The Takeda Oncology Company today reported ...ients from the large, international Phase III VIST...for patients with previously untreated multiple my...P). The VELCADE combination demonstrated consisten...ose with poor prognostic characteristics, such as ...
Other Medicine Technology:Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention 2Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6Anorectal Water Perfused Catheters
AnorectalSolid State Manometry Catheters
Multi-Use Adult Anorectal Water Perfused Catheters
Multi-Use Adult Esophageal Water Perfused Catheters
Medicine Products: